Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Surgical Tissue Flap to Bypass the Blood Brain Barrier in GBM

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03630289
Recruitment Status : Recruiting
First Posted : August 14, 2018
Last Update Posted : November 19, 2019
Sponsor:
Information provided by (Responsible Party):
John Boockvar, MD Zucker SOM @Hofstra/Northwell, Northwell Health

Brief Summary:

This study assesses the safety of using tissue autograft of a pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multiforme (GBM) patients.

The objective of the study is to demonstrate that this surgical technique is safe in a small human cohort of patients with resected newly diagnosed GBM and may improve progression-free survival (PFS).


Condition or disease Intervention/treatment Phase
Glioblastoma Glioblastoma Multiforme GBM Brain Cancer Procedure: Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB) Not Applicable

Detailed Description:

Glioblastoma (GBM) is the most common primary central nervous system malignancy in adults, and accounts for over half of all malignant brain tumors. The prognosis for newly diagnosed GBM is extremely poor even with Stupp protocol consisting of surgery followed by temozolomide and radiotherapy. Present therapies are inadequate, as evidenced by the low 5-year survival rate for brain cancer patients, with median survival at approximately 12 months and treatment for GBM remains a significant unmet clinical need in oncology.

All subjects included in the study will initially undergo standard surgical resection for newly diagnosed GBM. Following the resection, the surgical cavity will be lined with a long pedicled, autologous piece of tissue called a temporoparietal fascial flap or pericranium. The patient's dura, bone and scalp will be closed as is customary. The permeability of the blood vessels of the TPF or pericranial flap should allow for improved delivery of therapeutics and immune cells (macrophages and T cells) into the vicinity, extracellular space and microenvironment of the resected tumor cavity including the brain adjacent to the GBM. The TPF or pericranial flap would easily conform to many resected GBM cavities in our human patients with acceptable risk. The TPF and pericranial flap with its predictable and rich vascular anatomy have been shown to be an ideal flap for cases of previously irradiated and/or infected wound beds.

The investigators hypothesize that a TPF or pericranial flap that is harvested in our patients with resected GBM may be used as a readily available and accessible means of circumventing the blood brain barrier selectively and focally. The investigators aim to prove that this surgical technique is safe in a small human cohort of patients with resected newly diagnosed GBM and may improve progression-free survival (PFS).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Glioblastoma Multiforme (GBM)
Actual Study Start Date : July 27, 2018
Estimated Primary Completion Date : July 27, 2020
Estimated Study Completion Date : July 27, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Surgical tissue autograft: TPF flap/pericranial flap
Use of a pedicled autologous piece of tissue called the temporoparietal fascial (TPF) flap or pericranial flap into the resection cavity of newly diagnosed glioblastoma multiforme (GBM) patients
Procedure: Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB)
Surgical tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multiforme (GBM) patients.
Other Names:
  • surgical tissue flap
  • tissue autograft




Primary Outcome Measures :
  1. Safety parameter: proportion of patients experiencing rapidly progressive disease as indicated by MRI using RANO Criteria [ Time Frame: Study Day 1-180 ]
    Increase in tumor size relative to baseline will be measured using RANO and assessed by MRI throughout study at 24 hours, 7 days, 30 days, 60 days, 90 days, 180 days. Rapidly progressive disease is defined as 25% growth relative to baseline.

  2. Safety parameter: proportion of patients experiencing increase in seizures, stroke, and infection [ Time Frame: Study Day 1-180 ]
    Increase in seizures (defined as 15% relative to baseline), occurrence of a stroke, or occurrence of a severe infection will be determined throughout study at 24 hours, 7 days, 30 days, 60 days, 90 days, 180 days.


Secondary Outcome Measures :
  1. Progression Free Survival (PFS) [ Time Frame: 6 months ]
    The proportion of patients who are alive at 6 months from flap implantation and are progression-free will be estimated using standard methods for proportions, along with the associated exact 95% confidence interval. All patients will be followed for a minimum of six months from the time of implantation. For this analysis, patients who are lost to follow-up prior to 6 months will be (conservatively) assumed as treatment failures at 6 months. The investigators will also estimate PFS using the Kaplan-Meier Product Limit Method. For this analysis, subjects who are alive and have not progressed as of the date of last follow-up will be considered censored.

  2. Overall Survival (OS) [ Time Frame: 2 years ]
    OS will be calculated as the time from treatment initiation (TPF implantation) to the time of death. Subjects who are alive as of the date of last follow-up will be considered censored for survival. OS will be analyzed using the Kaplan-Meier Product Limit Method.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subject is a male or female 18 years of age or older.
  • Subject is undergoing planned resection of known or suspected GBM.
  • Subject has a Karnofsky Performance Status (KPS) 70% or greater.
  • Subject has a life expectancy of at least 6 months, in the opinion of the Investigator.
  • Based on the pre-operative evaluation by neurosurgeon, the subject is a candidate for ≥ 80% resection of enhancing region.
  • Subject must be able to undergo MRI evaluation.
  • Subject meets the following laboratory criteria:

    • White blood count ≥ 3,000/µL
    • Absolute neutrophil count ≥ 1,500/µL
    • Platelets ≥ 100,000/µL
    • Hemoglobin > 10.0 g/dL (transfusion and/or ESA allowed)
    • Total bilirubin and alkaline phosphatase ≤ 2x institutional upper limit of normal (ULN)
    • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN
    • Blood urea nitrogen (BUN) and creatinine < 1.5 x ULN
  • Females of reproductive potential must have a negative serum pregnancy test and be willing to use an acceptable method of birth control.
  • Males of reproductive potential must be willing to use an acceptable method of birth control to ensure effective contraception with partner.
  • Able to understand and willing to sign an institutional review board (IRB)-approved written informed consent document (legally authorized representative permitted).

Inclusion criteria considered during surgery:

  • Subject has a histologically confirmed (frozen section) diagnosis of WHO Grade IV glioblastoma multiforme (GBM).
  • TPFF and/or pericranial flap is technically feasible.

Exclusion Criteria:

  • Subject, if female, is pregnant or is breast feeding.
  • Subject has initiated chemotherapy or radiation treatment for diagnosis of or GBM.
  • Subject intends to participate in another clinical trial.
  • Subject intends to undergo treatment with the Gliadel® wafer at the time of this surgery.
  • Subject has an active infection requiring treatment.
  • Subject has radiographic evidence of multi-focal disease or leptomeningeal dissemination.
  • Subject has a history of other malignancy, unless the patient has been disease-free for at least 5 years. Adequately treated basal cell carcinoma or squamous cell skin cancer is acceptable regardless of time, as well as localized prostate carcinoma or cervical carcinoma in situ after curative treatment.
  • Subject has a known positive test for human immunodeficiency virus infection, or active hepatitis B or hepatitis C infection.
  • Subject has a history or evidence of any other clinically significant disorder, condition or disease that would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03630289


Contacts
Layout table for location contacts
Contact: John Boockvar, MD 212-434-4836 jboockvar@northwell.edu
Contact: Tamika Wong, MPH 212-434-4836 twong4@northwell.edu

Locations
Layout table for location information
United States, New York
Lenox Hill Brain Tumor Center Recruiting
New York, New York, United States, 10075
Contact: John Boockvar, MD    212-434-3900    jboockvar@northwell.edu   
Contact: Tamika Wong, MPH    212-434-4836    twong4@northwell.edu   
Principal Investigator: John Boockvar, MD         
Sub-Investigator: David Langer, MD         
Sub-Investigator: Peter Constantino, MD         
Sub-Investigator: Sherese Fralin, NP         
Sub-Investigator: Ashley Ray, NP         
Sub-Investigator: Christopher Filippi, MD         
Sub-Investigator: Tamika Wong, MPH         
Sub-Investigator: Lukas Faltings         
Sub-Investigator: Mona Li         
Sponsors and Collaborators
Northwell Health
Investigators
Layout table for investigator information
Principal Investigator: John Boockvar, MD Northwell Health
Layout table for additonal information
Responsible Party: John Boockvar, MD Zucker SOM @Hofstra/Northwell, Principal Investigator, Northwell Health
ClinicalTrials.gov Identifier: NCT03630289    
Other Study ID Numbers: 18-0498
First Posted: August 14, 2018    Key Record Dates
Last Update Posted: November 19, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by John Boockvar, MD Zucker SOM @Hofstra/Northwell, Northwell Health:
tissue autograft
blood brain barrier
Additional relevant MeSH terms:
Layout table for MeSH terms
Glioblastoma
Brain Neoplasms
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases